Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:56:32时区推断·⟳ 抓取 20:00:07·⚡ 决策 07-22 20:04:20 +4m13s·97.0 天前
Summit公布HARMONi三期更新OS数据并提交FDA审评补充资料
HARMONi更新数据显示西方患者OS风险比0.76，与亚洲患者一致，安全性未见新增信号，方向上支持ivonescimab BLA审评。
📄 原文Investing.com↗ 原文
Summit Therapeutics stock rises on positive cancer trial data
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven? Investing.com -- Summit Therapeutics Inc.…
不做 Summit Therapeutics（SMMT.US）
更新OS数据方向正面但不是统计显著性新达成或FDA批准，且SMMT已同向上涨；不追。
不做 康方生物（09926.HK）
康方为权益方但港股已当日上涨4.55%，本条未披露新增付款/销售量级，边际不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- 报道Summit披露HARMONi更新OS分析，西方患者HR为0.76，并称资料已提交FDA用于BLA审评。市场反应:SMMT.US上一交易日涨4.89%，09926.HK当日涨4.55%。
关键理由
- HARMONi更新数据显示西方患者OS风险比0.76，与亚洲患者一致，安全性未见新增信号，方向上支持ivonescimab BLA审评。
- 但2025年4月主要OS分析HR为0.79且p=0.057未达统计学显著，本次更多是随访更新和一致性补充，不是PDUFA前最终批准。
- Summit（SMMT.US）2026-07-21收14.16美元、当日涨4.89%；康方生物（09926.HK）2026-07-22收98.90港元、当日涨4.55%，核心数据已被当日市场反应消化。
主要风险
- PDUFA目标日期为2026-11-14，FDA是否认可OS补充资料仍有审评不确定性。
- 商业化量级仍取决于获批标签、定价、渗透率和Summit/康方权益分配，本条未披露新增销售或付款金额。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-06-30 · 影响 weakens
内部库已有6月30日专家访谈覆盖Summit/康方HARMONi管线，说明资产叙事并非全新；本次是更新数据，不是最终批准。
检索:Summit Therapeutics ivonescimab HARMONi OS FDA BLA PDUFA 2026 原文 ↗
工具调用 · 历史记录,结果未知(4 种)
- search_processed_events · 结果未知
- normalize_ticker · 结果未知
- price_snapshot · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,076 字
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
Investing.com -- Summit Therapeutics Inc. (NASDAQ:SMMT) rose 3% Wednesday following the release of updated overall survival results from its global Phase III HARMONi clinical trial evaluating ivonescimab plus chemotherapy.
The trial, which enrolled patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer previously treated with a third-generation EGFR tyrosine kinase inhibitor, showed Western patients achieved an overall survival hazard ratio of 0.76, consistent with Asian patients in the study.
In the most recent analysis with a data cut-off date in June 2026, the median follow-up time for Western patients reached 23.2 months, compared to 9.2 months at the time of the primary analysis in April 2025. The hazard ratio of 0.76 was observed in both the full intention-to-treat population and the subgroup of Western patients. The median follow-up time for Asian patients was 32.7 months.
The primary overall survival analysis performed in April 2025 showed ivonescimab in combination with chemotherapy demonstrated a positive trend with a hazard ratio of 0.79, though it did not achieve statistical significance with a p-value of 0.057. Median overall survival was 16.8 months for patients receiving ivonescimab plus chemotherapy versus 14.0 months for those receiving placebo plus chemotherapy.
Summit has made the updated analysis available to the FDA as part of its ongoing Biologics License Application review. The company’s BLA has a PDUFA goal action date of November 14, 2026. The study previously demonstrated a statistically significant benefit in progression-free survival, one of the trial’s two primary endpoints.
The company reported that ivonescimab continued to demonstrate an acceptable and manageable safety profile consistent with previous Phase III data, with no additional safety signals noted in the current data cut.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Investing.com -- Summit Therapeutics Inc. (NASDAQ:SMMT) rose 3% Wednesday following the release of updated overall survival results from its global Phase III HARMONi clinical trial evaluating ivonescimab plus chemotherapy.
The trial, which enrolled patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer previously treated with a third-generation EGFR tyrosine kinase inhibitor, showed Western patients achieved an overall survival hazard ratio of 0.76, consistent with Asian patients in the study.
In the most recent analysis with a data cut-off date in June 2026, the median follow-up time for Western patients reached 23.2 months, compared to 9.2 months at the time of the primary analysis in April 2025. The hazard ratio of 0.76 was observed in both the full intention-to-treat population and the subgroup of Western patients. The median follow-up time for Asian patients was 32.7 months.
The primary overall survival analysis performed in April 2025 showed ivonescimab in combination with chemotherapy demonstrated a positive trend with a hazard ratio of 0.79, though it did not achieve statistical significance with a p-value of 0.057. Median overall survival was 16.8 months for patients receiving ivonescimab plus chemotherapy versus 14.0 months for those receiving placebo plus chemotherapy.
Summit has made the updated analysis available to the FDA as part of its ongoing Biologics License Application review. The company’s BLA has a PDUFA goal action date of November 14, 2026. The study previously demonstrated a statistically significant benefit in progression-free survival, one of the trial’s two primary endpoints.
The company reported that ivonescimab continued to demonstrate an acceptable and manageable safety profile consistent with previous Phase III data, with no additional safety signals noted in the current data cut.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。